Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2022 / Apr / Epigenetics of Early Arrivals
Genetics and epigenetics Molecular Pathology

Epigenetics of Early Arrivals

Epigenetic testing could identify those at risk of preterm birth

By Liv Gaskill 04/26/2022 News 1 min read

Share

Credit: Image from Shutterstock.com

The World Health Organization estimates that 15 million babies – over 10 percent – are born prematurely every year, risking major health problems for survivors both immediately and later in life. But what if you could identify pregnant individuals at risk of giving birth prematurely and put a clinical management plan in place to delay or prevent it? “The problem is that there are currently no efficient clinical biomarkers for preterm birth susceptibility, prompting me and my team to explore a noninvasive option with epigenetic biomarkers,” says Michael Skinner, senior author of a new study that aimed to identify markers of preterm birth (1).

In the study, the team collected buccal cells from cheek swabs of the mother, father, and child in both full and preterm births, then analyzed them to identify differential DNA methylation regions (DMRs). They identified 165 epigenetic DMRs in mothers of preterm babies that were different to those in full-term mothers, as well as 136 such DMRs in female preterm children, suggesting that epigenetic inheritance may play a role in preterm birth. Fathers of preterm births had fewer DMRs than mothers and children, but the epigenetic signature was still sufficient to indicate a potential paternal role. The signature was not found in male preterm infants. The results demonstrate that DNA methylation changes in the mother, father, and female children could act as biomarkers of preterm birth.

The research is a proof-of-concept study, so a larger clinical trial is now needed to improve and validate the epigenetic signatures. “Our findings have significant potential to improve population health and reduce disease burden in later life, while saving many children’s lives after severe early preterm birth,” says Skinner. “For mothers, epigenetic testing could help to avoid the stress and complications caused by preterm birth – a major problem in perinatal health – and improve preventative options for preterm birth treatment.”

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. P Winchester et al., Sci Rep, 12, 3361 (2022). PMID: 35232984.

About the Author(s)

Liv Gaskill

During my undergraduate degree in psychology and Master’s in neuroimaging for clinical and cognitive neuroscience, I realized the tasks my classmates found tedious – writing essays, editing, proofreading – were the ones that gave me the greatest satisfaction. I quickly gathered that rambling on about science in the bar wasn’t exactly riveting for my non-scientist friends, so my thoughts turned to a career in science writing. At Texere, I get to craft science into stories, interact with international experts, and engage with readers who love science just as much as I do.

More Articles by Liv Gaskill

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Breathing New Life into Diagnostics
Genetics and epigenetics
Breathing New Life into Diagnostics

January 22, 2024

6 min read

Jonathan Edgeworth on how metagenomics could transform testing for respiratory infections

Molecular Spectacular
Genetics and epigenetics
Molecular Spectacular

January 8, 2024

1 min read

A look at last year’s most interesting molecular pathology stories

Redefining Diagnostic Reference Standards
Genetics and epigenetics
Redefining Diagnostic Reference Standards

January 3, 2022

1 min read

Find out what Horizon Discovery’s diagnostic reference standards can do for your workflow

Defining the Next Generation of NGS
Genetics and epigenetics
Defining the Next Generation of NGS

December 31, 2021

1 min read

Overcoming challenges of the typical NGS workflow with the Ion Torrent™ Genexus™ System

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.